Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pAC1-V16-eGFP
(Plasmid #122033)

Ordering

Item Catalog # Description Quantity Price (USD)
Plasmid 122033 Standard format: Plasmid sent in bacteria as agar stab 1 $85

This material is available to academics and nonprofits only.

Backbone

  • Vector backbone
    pAC1
  • Backbone manufacturer
    Chtarto et al 2003 GeneTher 10 (84-94)
  • Vector type
    AAV

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    eGFP
  • Species
    Aequorea victoria
  • Insert Size (bp)
    720

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site unknown (unknown if destroyed)
  • 3′ cloning site unknown (unknown if destroyed)
  • 5′ sequencing primer n/a
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pAC1-V16-eGFP was a gift from Liliane Tenenbaum (Addgene plasmid # 122033 ; http://n2t.net/addgene:122033 ; RRID:Addgene_122033)
  • For your References section:

    A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses. Chtarto A, Humbert-Claude M, Bockstael O, Das AT, Boutry S, Breger LS, Klaver B, Melas C, Barroso-Chinea P, Gonzalez-Hernandez T, Muller RN, DeWitte O, Levivier M, Lundberg C, Berkhout B, Tenenbaum L. Mol Ther Methods Clin Dev. 2016 Mar 30;5:16027. doi: 10.1038/mtm.2016.27. eCollection 2016. S2329-0501(16)30169-3 [pii] PubMed 27069954